

PCTriADD

PROSTATE CENTRE'S TRANSLATIONAL RESEARCH INITIATIVE
FOR ACCELERATED DISCOVERY AND DEVELOPMENT

Building for the Future


PC-TRIADD Annual Report 2010 – 2011



VANCOUVER
PROSTATE CENTRE
A UBC & VGH Centre of Excellence

Table of Contents

About Us	1
Director's Message	2
Building and Expanding Services through Business Units	5
PCTRIADD's Microarray Facility Evolves into a Laboratory for Advanced Genome Analysis	
Clinical Trials	
CTAG & Biorepository	
Analytical Pharmacology and Drug Design	
Building Collaborations	8
Building Future Solutions - Research	9
Building Client Relationships	9
Building Value - Intellectual Property, People and Reputation	10
Building Buildings	12
Building Commercial Innovation	14
Financial Highlights	15
Partnerships and Collaborations	16
Leadership Team	17



About Us

Prostate Centre's Translational Research Initiative for Accelerated Discovery and Development (PC-TRIADD) is a translational cancer research centre and designated Centre of Excellence for Commercialization and Research (CECR) focused on discovering and developing new interventions to improve outcomes in prostate and other cancer.

Funded by the Government of Canada, PC-TRIADD also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as gene and pathway discovery, biomarker analyses, preclinical testing, tumour biology, novel drug discovery, and clinical expertise. This model not only enables us to attract more revenue-generating contract research agreements, but it also supports and leverages value-added development of our internal discoveries which creates new IP, services, and products.

PC-TRIADD host institutions are:

The Vancouver General Hospital and Vancouver Coastal Health Research Institute

Vancouver Coastal Health Research Institute is the research body of Vancouver Coastal Health Authority, which includes BC's largest academic and teaching health sciences centres: VGH, UBC Hospital, and GF Strong Rehabilitation Centre. In academic partnership with the University of British Columbia, VCH Research Institute brings innovation and discovery to patient care, advancing healthier lives in healthy communities across British Columbia, Canada, and beyond. www.vchri.ca

The University of British Columbia, Faculty of Medicine

The UBC Faculty of Medicine provides innovative programs in the health and life sciences, teaching students at the undergraduate, graduate and postgraduate levels, and generates more than \$200 million in research funding each year. In 2007/08, out of the total UBC research endeavour, 53 per cent, or \$247 million, came from academic and clinical teams in the Faculty of Medicine. www.med.ubc.ca

Our Mission

The mission of the PC-TRIADD Centre of Excellence for Commercialization and Research is to serve as a hybrid between academic research and the biotechnology industry, and to foster the paradigm of team-driven translational health research. Our aim is to discover molecular mechanisms of cancer progression and therapeutic resistance and use this information to develop new services and products to improve cancer outcomes and promote regional growth of biotechnology.

“Our core research focus is understanding the mechanisms of prostate cancer resistance and developing new therapeutic options for patients with advanced prostate and other cancers.”

—Dr. Martin Gleave, Executive Director,
Vancouver Prostate Centre



A Message from our Director

Building Strength and Capacity

Dr. Martin Gleave, MD, FRCSC, FACS

Executive Director, Vancouver Prostate Centre

Chief Executive Officer, PC-TRIADD


Distinguished Professor, Department of Urologic Sciences, UBC

BC Leadership Chair in Prostate Cancer Research

For PC-TRIADD, year one was all about **momentum**. In year two we focused on the **impact** of our activities. While we maintain our momentum and continue to have an impact on our health, communities and economy, we're characterizing the 2010/2011 year as one of **building for the future**.

It's a fitting theme both literally and figuratively. Literally we witnessed the completion of the Robert H.N. Ho Research Centre building and already our researchers and staff have started to take occupancy. This 69,350 sq.ft. modern facility, along with the adjacent Jack Bell Research Centre and the Gordon and Leslie Diamond Health Care Centre, now house the expanded Vancouver Prostate Centre. These additional facilities have enabled us to build and equip state-of-the-art labs and expand our services and deepen our expertise, which is attracting new clients and new revenue sources. In particular, you'll read about how we've built a world-class laboratory for Advanced Genome Analysis (LAGA) and how we've expanded our biorepository and drug design capabilities.

Figuratively, with a strong foundation in place, we've been able to build and strengthen our capacity, expertise, services, client-base, collaborations and intellectual property.



Our expanded capability and expertise in genomics, molecular biology, and translational pre-clinical and clinical studies continue to attract collaborative research opportunities with global pharmaceutical companies. In 2010/2011, we signed over \$2.1 million worth of new agreements. And through our key role as co-coordinating centre for national clinical trials networks, we anticipate generating over \$15 million in revenue back to the national clinical trials infrastructure, specifically through two important trials for OncoGenex Pharmaceuticals.

We've built and leveraged initial investments. By using CECR funding to seed pre-competitive projects, we've seen those projects build and attract further funding. Some are now emerging as revenue-generating services. For example, we can now help clients to identify novel drug candidates using a brand new field of genomics called computational chemogenomics, which when coupled with our gene sequencing capabilities and biorepository, offers unique capacities to match drug-to-gene more rapidly.

We continue to build our reputation as a world-class prostate research centre through national and international collaborations —most recently with Novartis Pharmaceuticals and the International Cancer

Genome Consortium (ICGC)—and through important research programs. One such program is our research into Circulating Tumour Cells, which are emerging as an important marker for cancer progression.

We've seen innovations initiated at Vancouver Prostate Centre, build into enterprises that are now taking the research forward to commercialization. One spin-off, OncoGenex Pharmaceuticals, was named Canadian biotech company of the Year in 2010, reported very promising results from a Phase 2 clinical trial for its drug OGX-011. OGX-011 is now in 3 large Phase III registration studies.

There's no question, the caliber of people we've been able to attract and retain has been a huge part of our success in building our capability, capacity, reputation and business. We remain committed to developing high-quality personnel—the next generation of research scientists and entrepreneurs—by providing rich cross-training opportunities.

I would like to thank our staff for all their valuable contributions this year. I would also like to express my gratitude to the Board of Directors for their support. We have every intention of building upon what we've achieved to date, into the future.


Dr. Martin Gleave

.....
“I was attracted to the Vancouver Prostate
Centre from the University of California
by the talent, the reputation and the
state-of-the-art facilities that were made
available to me as a researcher.”

—Dr. Colin Collins



Building and Expanding Services through Business Units



Building a World Class Laboratory for Advanced Genome Analysis (LAGA)

What started as the high throughput bioprofiling platform in 1998 and expanded as the largest microarray facility in Western Canada, today has become a multi-platform innovation centre for advanced genome analysis.

Equipment

Fueled by federal funding from the CECR program and the Canadian Foundation for Innovation (CFI), the Laboratory for Advanced Genome Analysis (LAGA) now occupies 1,600 square feet of laboratories and offices within the Vancouver Prostate Centre. It also houses state-of-the-art equipment including a dedicated GAll sequencer installed at the BC Cancer Agency's Genome Science Centre. This core facility has a complete suite of robotics, and a diverse suite of software tools to analyze, integrate, and visualize data. A new data center that provides over 140 Terabytes of storage will accommodate six additional IBM xSeries servers.



Expertise

CECR funding also enabled us to recruit highly qualified personnel (HQP) to run the core facility. In particular, Dr. Colin Collins was recruited from the University of California San Francisco Comprehensive Cancer Center in 2009 to co-direct the laboratory and lead a multidisciplinary translational prostate cancer genomics effort linking the Vancouver Prostate Centre with the Genome Sciences Centre. A world renowned Cancer Genetics Scientist, Dr. Collins adds significant expertise in translational genomics, sequence data analysis, and in developing sophisticated computational tools for analyzing, integrating, and visualizing sequenced genomes and transcriptomes and array-based data. Additional scientists, Drs Anna Lapuk and Stanislav Volik, were recruited to the laboratory, further expanding the group's expertise. This centre now employs 14 HQPs, providing unique state-of-the-art genomics support to the Vancouver Prostate Centre and broader community at UBC, BC Cancer Agency, and SFU.

Expanded Services

Today LAGA supports and integrates rapidly evolving genomic technologies, computer science, and informatics and functions as an incubator to develop and translate new innovations, technologies, and bioinformatics tools. While LAGA prioritizes projects within PC-TRIADD, it also provides regional, national and international researchers with the highest quality results through access to the latest genomics technologies. From a commercial perspective, the sophisticated equipment and deep expertise within the centre has also attracted heavy-weights such as Takeda, Pfizer and Novartis. To date, this has attracted over \$500,000 of collaborative research agreements to the laboratory, propelling it toward self sufficiency by 2012.

To expand the bioinformatics and computer science expertise even further, a new collaboration with Dr. Cenk Sahinalp's Laboratory for Computational Biology at Simon Fraser University (SFU) was established this year.



Conducting High-Value Clinical Trials

Clinical trials are a core service and are conducted in close partnership with the BC Cancer Agency, national and international clinical trials networks, and industry partners. With the reduction of risk capital available for biotech, the global financial crisis, and a trend towards more trials in Eastern Europe and Asia, Canada's competitiveness trials have been reduced by 25% and enrollment numbers have decreased. The good news is the trials that are conducted through the PC-TRIADD's Clinical Trials Unit are more complex and high-value so revenues remained stable this year.

Through our key role as co-coordinating centre for national clinical trials networks we have been able to attract significant revenues back into Canada from global Pharmaceutical companies. A prime example of this is the investment by TEVA Pharmaceuticals in Canada for its Phase 3 program with OGX-011, where enrollment is expected to include up to 150 Canadian patients, which is expected to generate \$10 million in revenue back to the centres participating in these national clinical trials. Correlative science studies will attract even further funding opportunities. Additionally, a Phase 2 trial of OGX-427, also funded by a grant from the Terry Fox Research Institute and OncoGenex, is expected to generate a further \$5 million across for Canada. Dr Kim Chi, head of our clinical trials unit, is global Principal Investigator for these studies, all emanating from our discoveries and early development of OGX-011 and OGX-427.

Clinical Trial Patient Enrollment per Year

Year	08/09	09/10	10/11
All treatment studies*	92	88	91
Nomogram/Canary and Phase 1 studies	87	68	25
Total	179	156	116
New trials commenced	-	-	9

* Not including Phase 1, Nomogram or Canary Active surveillance studies

Centre for Translational and Applied Genomics (CTAG) Achieves Self Funding Status

After 3 years of consecutive revenue growth of 50 percent per year, this year CTAG became a self-funding business unit. CTAG, a division of Provincial Health Services Authority Laboratories, is a translational genomics research facility.


Additionally, CTAG was granted full accreditation status by the College of American Pathologists (CAP). CAP is the world's largest association composed exclusively of pathologists certified by the American Board of Pathology and is widely considered the leader in laboratory quality assurance.

CTAG is the only research laboratory to be accredited in Western Canada, and one of only a few nationally. Research laboratories are a relatively new category for CAP, which typically accredits routine diagnostic facilities. This accreditation also means this centre, can be used for the analysis of specimens derived from clinical trials.

Expanding the Prostate Biorepository

This year, we streamlined the operational performance of the biorepository and expanded its facilities and storage capacity. This expansion makes this Canadian biorepository a unique global resource that furthers prostate research. Indeed, numerous researchers from both the academic and industrial sectors are accessing this unique resource in the search for novel targets to identify potential new therapies.


Our tumour bank contains well over 2000 prostate cancer specimens (both fresh frozen and paraffin embedded). This resource of human prostate tumour tissues is a key asset to identify new tumour targets, and develop tumour models to validate new therapeutic agents. We are also working with Drs Fred Saad (U of Montreal) and Rob Bristow (U of Toronto) to build a large Pan-Canadian tissue microarray to facilitate biomarker discovery and validation. This initiative is funded by the Terry Fox Research Institute.



Preclinical Pharmacology Services Expanded to provide Drug Design Capabilities




Our comprehensive preclinical pharmacology expertise has been expanded to include a specialized new expertise in drug design. Under the leadership of Dr. Art Cherkasov, a researcher at the Vancouver Prostate Centre and Associate Professor, Dept. of Urologic Sciences - UBC, the unit can now help clients to identify novel drug candidates using a brand new field called computational chemogenomics. This new approach uses computer modeling in virtual 3D to predict how different chemicals or drugs will affect cancer tumours. Indeed, Vancouver Prostate Centre researchers are using computational chemogenomics to tackle the deadliest forms of prostate cancer through a project titled "Methods of Chemical Genomics". This project received \$324,000 in funding this year, with \$161,500 from Genome BC, and the rest from other partners, including the Canadian Institutes of Health Research and Vancouver Prostate Centre.

The ability to offer this specialized service was seeded a few years ago with a proof-of-concept grant using CECR funds. That allowed the group to expand, build and attract further grants to build this unique expertise which is now garnering the attention of clients.



“Dr. Cherkasov is one of a handful of experts in the world with expertise in computational chemogenomics and he’s built a strong team of cheminformatic drug design specialists to offer drug design capabilities within our preclinical pharmacology core.”

— Dr. Martin Gleave, Executive Director



Building Collaborations

Improving Patient Selection for Clinical Trials

In January 2011, we announced a one-year collaborative project with Novartis Pharmaceutical Corporation. The project will use cutting-edge technology to identify and validate the molecular targets that predict cancer sensitivity or insensitivity to specific inhibitors. Ultimately, these insights may enable clinicians to more accurately select patients who are likely to benefit from a particular clinical trial.

Leverage Resources and Expertise to Develop Anti-Cancer Therapeutics

The Centre for Drug Research and Development (CDRD) and PC-TRIADD, both Centres of Excellence in Commercialization and Research announced that they have signed a preferred collaboration agreement as the two organizations jointly strive to accelerate the discovery, development and commercialization of anti-cancer therapeutics.

“As two of a select group of organizations that have been named ‘Centres of Excellence in Commercialization and Research,’ we have found a way to further leverage our funding and expertise to ensure that new cancer therapeutics will be developed and commercialized.”

—Natalie Dakers, CEO,
Centre for Drug Research and Development

This is not the first time these groups have come together. Last March, Queensland Premier Anna Bligh announced a \$1.53 million Smart Futures Fund grant to support a new \$6.2 million Queensland-British Columbia Drug Discovery Alliance between Griffith University’s Eskitis Institute in Queensland, the Vancouver Prostate Centre and the CDRD.



PC-TRIADD and Eskitis Institute are also in year two of a \$525K three-year project NIRAP grant by the Queensland Government for a new drug discovery program.

Sequencing the Prostate Cancer Genome

The Vancouver Prostate Centre was named as part of a highly collaborative project which brings together Canadian researchers working in Vancouver, Calgary, Toronto, Kingston and Montreal as well as, international research teams based in the United Kingdom, France and Germany. The announcement was made by the International Cancer Genome Consortium (ICGC) last February 2011, where they announced the launch of a \$20 million Canadian research project that will map the genetic structure of prostate cancer and provide new information that could greatly improve the diagnosis and treatment of the disease.

“We are excited by the possibility to use precise genetic information from our patients to personalize their prostate cancer diagnosis and treatment. This personalized medicine approach will, no doubt, improve the quality of life for men worldwide diagnosed with the disease.”

—Dr. Robert Bristow, Senior Scientist at the Ontario Cancer Institute, the research arm of the University Health Network’s Princess Margaret Hospital (PMH) and ICGC project lead.



Building Future Solutions—Research

Circulating Tumour Cells Emerge as an Important Marker for Cancer Progression

Research into circulating tumour cells (CTCs) -- the cells that break off from the main tumour and float around in the blood stream -- took a major step forward this year with supporting evidence that CTCs are evolving as an important surrogate marker in prostate and other cancer types. It is believed that CTC's serve as a rapid surrogate to predict which patients are the best match for drug treatments, or give early indications that treatments are working.

Currently, we are the only centre in BC that houses the FDA-approved Veridex technology for quantifying CTC's in clinical trials. CTC measurements are showing promise as a new tool to quantify response of cancers to new treatments. This technology

is being used by Dr. Kim Chi in ongoing clinical trials in endometrial cancer, with Paris-based Ipsen Innovations, a global biopharmaceutical specialty care group, and in prostate cancer, with TEVA Pharmaceutical Industries and OncoGenex. As part of a Phase I program with OGX-427, we developed and used a CTC measurements in patients treated with OGX-427 and saw consistent, dose dependent decreases in CTC counts after OGX-427 treatment. This test will also be used to support correlative studies in both the Phase III studies of OGX-011 and Phase II studies of OGX-427.

Further research is also being conducted by UBC and Vancouver Prostate Centre researchers, Drs. Hong Ma and Peter Black who are currently studying new and more sensitive methods to isolate and detect these circulating tumour cells using novel technology.

Building Client Relationships

Agreements with Pharmaceutical and Biotech Companies Continue to Grow

Our capabilities continue to attract collaborative research opportunities with major pharmaceutical companies. In 2010/2011 we signed over \$2.1M worth of new collaborative research agreements. The following is a list of clients who have sought out our expertise in prostate cancer and tumour models, and are investing in testing potential new drugs in Canada.



Building Value— Intellectual Property, People and Reputation

14

New Patents filed

We continued to generate Intellectual Property and expand its portfolio with 7 provisional and 7 divisional/national patent actions. Five of these patents derived from precompetitive research projects directly funded by PC-TRIADD.



4

Pre-competitive projects that have taken flight

Seed investments using CECR funds to initiate pre-competitive projects in 2009 and 2010 have started to take root in 2011. These projects have attracted further grants, leveraging the initial investment, or have now been expanded into revenue generating services.

132

Publications published



120

Presentations presented

@25

Conferences



Our researchers

continue to produce high quality research with significant impact and outcomes with 132 publications in significant scientific journals, such as *the Journal of Clinical Oncology*, *Cancer Research*, *Cancer Cell*, *EMBO*, and the *New England Journal of Medicine*.

The four projects are:

- 1 In Silico Drug design for BF-3 Binding Drugs.
- 2 Semaphorin 3C as a novel target for treatment of advanced prostate cancer.
- 3 The enumeration of circulating tumor cells (CTCs) as a rapid surrogate for the activity of anti-cancer drugs.
- 4 Therapeutic potential of recombinant clusterin protein in the protection of renal ischemia-reperfusion injury.

“I came to Vancouver to work at the Prostate Centre where I knew I’d be part of a multi-disciplinary team with a big vision. It is the very best place for me to study translational research and basic science at the same time.”

—Dr. Amina Zoubeidi

63



High Quality Trainees trained

A key objective of the PC-TRIADD is to not only attract and retain high-quality personnel, but also to provide cross-training opportunities in genomics, proteomics, bioinformatics, pathology, tumour biology, oncology, pharmaceutical sciences, clinical trials, contract research and business. This year we trained 2 clinical fellows, 21 post-docs, 20 graduate students (15 Ph.D., 5 M.Sc.) 15 Co-op and 5 summer students being trained within the Centre.



Financial Award:

Dr. Amina Zoubeidi



A research scientist with the Vancouver Prostate Centre and an assistant professor, Department of Urologic Sciences, UBC is one of four scientists to receive an award from the Terry Fox Foundation’s New Investigator Awards Program valued at almost \$450,000 over the next three years.

14

Awards

bestowed on Vancouver Prostate Centre faculty and trainees

Awards and recognitions are a testament to the level of expertise, quality and ingenuity of our people. This year, our faculty garnered five major awards and commendations from various national and international organizations. Nine awards were given to 10 of our trainees (Students, Residents, Clinical Fellows and Post-Doctoral Fellows Awards) from organizations including our host the Vancouver Coastal Health Research Institute.

Building Buildings



New Facility Supports Future Growth and Expansion

Researchers and other personnel have started to occupy space in the new, progressive Robert H.N. Ho Research Centre, a 69,320 square foot facility located at the Vancouver General Hospital. The facility will be home to three key research programs including the Vancouver Prostate Centre. This additional space almost doubles Vancouver Prostate Centre's current lab and office area.

The facility was built as a result of two large federal Canada Foundation for Innovation (CFI)-funded grants to PC-TRIADD totalling \$24.7 million. The Provincial contribution was \$22.5 through the Ministry of Health Services and Small Business, Technology and Economic Development. Additionally, we are very thankful to a generous donation of \$15 million from philanthropist Mr. Ho, which completed the private sector funding match.

The expanded Vancouver Prostate Centre now occupies approximately 75,000 sq ft of lab and office space in the Robert Ho Building along with the adjacent Jack Bell Research Centre and the Gordon and Leslie Diamond Health Care Centre. The 22,00 sq ft of new space in the Robert H N Ho building allows for expansion, increased capacity and the ability to undertake more contract research, which increases revenue.


“One of the most striking aspects of the exterior design is the seemingly haphazard spacing (and curved shape) of windows on the north and south sides. To the uninitiated they resembled dots and dashes, but the inspiration came from DNA markers”

—Renante Solivar
Musson Cattell Mackey Partnership



“This space provides a functional, yet aesthetically pleasing working environment that encourages collaboration and efficiencies through common areas and common equipment. It also allows for the expansion of our Advanced Genomics and Preclinical Services by providing fully equipped state of the art labs and facilities.”

—Dr. Paul Rennie, Director, Laboratory Research, Vancouver Prostate Centre



Building Commercial Innovation

OncoGenex Pharmaceuticals

OncoGenex, a biopharmaceutical company spun out of the Vancouver Prostate Centre and co-founded by Dr. Martin Gleave, recently reported positive Phase 2 results for its drug OGX-011. The results indicated that the drug extended the life of patients with advanced prostate cancer by about seven months above and beyond what was achieved with chemotherapy alone. This combination doubles life expectancy, compared with a decade ago prior to the availability of docetaxel. The findings, written by a team of scientists led by Drs. Chi and Gleave, were published in the October 2010 edition of the *Journal of Clinical Oncology*.

We continue to work with OncoGenex through our Pre-Clinical Pharmacology Unit to further understand its lead compounds, and advance and add value to potential products.

Global Phase 3 Trials Now Underway: Teva Pharmaceuticals Industries Ltd. and OncoGenex recently announced the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011) as first line therapy for the treatment of castrate-resistant prostate cancer. The SYNERGY

trial is the second of three Phase 3 trials to be initiated under a global collaboration and license agreement between Teva and OncoGenex to develop and commercialize custirsen. The Phase 3 trial in Canada will be conducted through the PC-TRIADD Clinical Trials unit and will include 100 – 150 patients, giving them access to potential life extending treatment.

Aquinox Pharmaceuticals

A spin-off company from research conducted at UBC, BC Cancer Agency and Vancouver Prostate Centre, Aquinox is now a private, venture-backed biopharmaceutical company committed to the discovery, development and commercialization of novel and targeted small molecule therapeutics to treat inflammatory disease and cancer. Dr Chris Ong head of our preclinical pharmacology team was a founder. Aquinox recently announced the initiation of a Phase I clinical trial of its lead compound, AQX-1125, a novel oral anti-inflammatory compound. In June 2010, Aquinox raised \$25 M US to fund their program, including the clinical development of AQX-1125.

Statement of Financial Position

March 31, 2011, with comparative figures for 2010

	2011	2010
Assets		
Current assets		
Cash	\$ 672,522	\$ 533,615
Investments	4,557,485	3,607,167
	5,230,007	4,140,782
Investments	5,588,867	8,178,811
	\$ 10,818,874	\$ 12,319,593
Liabilities and Net Assets		
Current liabilities		
Accounts payable and accrued liabilities	\$ 565,696	\$ 365,983
Deferred revenue	8,938,627	11,004,433
Net assets:		
Unrestricted	1,314,551	949,177
	\$ 10,818,874	\$ 12,319,593

Statement of Revenue and Expenses and Changes in Net Assets

Year ended March 31, 2011, with comparative figures for 2010

	2011	2010
Revenue		
CECR Program funds	\$ 2,065,806	\$ 2,168,658
Interest income	365,374	449,010
	2,431,180	2,617,668
Expenses:		
Funding of research expenses incurred by Vancouver Coastal Health Authority	1,958,372	2,059,535
Funding of research expenses incurred by Provincial Health Services Authority	81,156	93,550
Funding of research expenses incurred by University of British Columbia	26,208	15,356
Miscellaneous	70	217
	2,065,806	2,168,658
Excess of revenue over expenses	\$ 365,374	\$ 449,010
Net assets, beginning of year	949,177	500,167
Net assets, end of year	\$ 1,314,551	\$ 949,177




On behalf of the Board, the undersigned confirm that the Board of Directors has approved the Annual Report for 2010/2011 as presented. A full set of audited financial statements is available.

Yours truly,

Michael O'Keefe
Chairman
Board of Directors

Dr. Martin E. Gleave
Executive Director

Mae Locke
Chief Financial Officer



Leadership Team

Our Management Team

Dr. Martin Gleave,
Chief Executive Officer
and Executive Director,
Vancouver Prostate Centre

Dr. Larry Goldenberg,
Vice President, Development,
Vancouver Prostate Centre, and Head,
Department of Urologic Sciences, UBC

Dr. Paul Rennie,
Vice President, Laboratory Research,
Vancouver Prostate Centre

Dr. Graeme Boniface,
Chief Operating Officer,
Vancouver Prostate Centre

Ms. Mae Locke,
Chief Financial Officer,
Vancouver Prostate Centre

Our Business Unit Leaders

Dr. Colin Collins, Dr. Colleen Nelson,
Co-Directors, Laboratory for
Advanced Genome Analysis (LAGA)

Dr. David Huntsman, Director,
Centre for Translational and
Applied Genomics (CTAG)

Dr. Emma Guns, Dr. Art Cherkozoff,
Analytical Pharmacology and
Drug Design Unit

Dr. Christopher Ong, Head,
Preclinical Pharmacology Unit

Dr. Kim Chi, Medical Director, Genitourinary
Clinical Trials Unit, BC Cancer Agency

Dr. Alan So, Vancouver Prostate Centre

Our Board of Directors

Mr. Michael O'Keefe – Chair

Mr. Richard Bradshaw

Dr. Graeme Boniface

Mr. Scott Cormack

Ms. Karimah Es-Sabar

Dr. Martin Gleave

Dr. Larry Goldenberg

Mr. Robert Mair

Mr. David McLean

Dr. Robert McMaster

Dr. David Ostrow

Mr. Conrad Pinette

Mr. George Richards

Dr. Ken Spencer

Partnerships & Collaborations

Our Host Institutions



Our Partners





PCTriADD

PROSTATE CENTRE'S TRANSLATIONAL RESEARCH INITIATIVE
FOR ACCELERATED DISCOVERY AND DEVELOPMENT

2660 Oak Street
Vancouver BC
Canada V6H 3Z6

Tel: 604 875 4818
Fax: 604 875 5654
www.pctriadd.com



**VANCOUVER
PROSTATE CENTRE**
A UBC & VGH Centre of Excellence